CMPD-39

• Description:

  CMPD-39 is a selective non-covalent inhibitor of the ubiquitin-specific protease USP30 (IC50=~20 nM), with high selectivity over other DUB family members (1-100 μM) . CMPD-39 inhibits the deubiquitinating activity of USP30, enhances the ubiquitination of mitochondrial proteins TOMM20 and SYNJ2BP; thus, CMPD-39 promotes phosphoubuitin accumulation, thereby accelerating mitochondrial autophagy (mitophagy) and peroxisomal autophagy (pexophagy) . CMPD-39 significantly restores impaired mitochondrial function in dopaminergic neurons derived from Parkinson's disease patients[1][2].

• UNSPSC:

  12352005

• Target:

  Deubiquitinase; Mitophagy

• Type:

  Reference compound

• Related Pathways:

  Autophagy; Cell Cycle/DNA Damage

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/usp30-inhibitor-18.html

• Purity:

  99.74

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  CC(C)(C)NS(=O)(C1=CC=C(C=C1)NC([C@@H](NC(C2=CC=C(C=C2)F)=O)CC3=CC=CC=C3)=O)=O

• Molecular Formula:

  C26H28FN3O4S

• Molecular Weight:

  497.58

• References & Citations:

  [1]Arthur F Kluge, et al. Novel highly selective inhibitors of ubiquitin specific protease 30 (USP30) accelerate mitophagy. Bioorg Med Chem Lett. 2018 Aug 15;28 (15) :2655-2659.|[2]Rusilowicz-Jones EV, et al. Benchmarking a highly selective USP30 inhibitor for enhancement of mitophagy and pexophagy. Life Sci Alliance. 2021;5 (2) :e202101287.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  USP30

• CAS Number:

  [2242582-40-5]